Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis

被引：0

作者：

Bernard Combe

Robin Besuyen

Antonio Gómez-Centeno

Tsukasa Matsubara

Juan José Sancho Jimenez

Zhaoyu Yin

Maya H. Buch

机构：

[1] University of Montpellier,NIHR Manchester Biomedical Research Centre

[2] Galapagos BV,undefined

[3] Hospital Universitari Parc Tauli,undefined

[4] Sabadell,undefined

[5] Matsubara Mayflower Hospital,undefined

[6] Galapagos,undefined

[7] Gilead Sciences,undefined

[8] Inc.,undefined

[9] University of Manchester,undefined

来源：

Rheumatology and Therapy | 2023年 / 10卷

关键词：

Adverse effects; Disease-modifying antirheumatic drug; Filgotinib; Outcomes; Rheumatoid arthritis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Clinical trials in rheumatoid arthritis recruit too few patients from diverse ethnic backgrounds to be able to identify differences in treatment outcomes. In adults with moderate-to-severe active rheumatoid arthritis who do not tolerate or have responded poorly to other advanced treatments, the Janus kinase inhibitor filgotinib can be used alone or in combination with the immunosuppressant methotrexate. Using data from 4695 patients with rheumatoid arthritis from five previous clinical trials and two ongoing trial extensions, this paper examined the efficacy and safety of filgotinib in patients with rheumatoid arthritis across geographic locations worldwide.

引用

页码：35 / 51

页数：16

共 104 条

[11] Badsha H(2021)Filgotinib in rheumatoid arthritis: a profile of its use Clin Drug Investig 41 848-325
[12] Shapira Y(2021)Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial Ann Rheum Dis 80 315-1008
[13] Agmon-Levin N(2019)Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial JAMA 322 998-1019
[14] Shoenfeld Y(2017)Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1) Ann Rheum Dis 76 1009-1238
[15] Massardo L(2017)Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) Ann Rheum Dis 76 1230-192
[16] Pons-Estel BA(2021)Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of Phase II rheumatoid arthritis programs J Rheumatol 48 184-2581
[17] Wojdyla D(2022)Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years Ann Rheum Dis 81 2569-738
[18] Burgos-Vargas R(2010)2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Arthritis Rheum 62 727-8.e1
[19] Catoggio LJ(2021)Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial Ann Rheum Dis 80 622-1246
[20] Galarza-Maldonado C(2013)Rheumatoid arthritis and cardiovascular disease Am Heart J 166 271-1307

← 1 2 3 4 5 6 7 8 9 10 →